Multiple Sclerosis, associated symptoms & CBD 1% Cream

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress.

Posted by Joe Pavlik on

Published: Cell Death Dis. 2012 Jun 28;3:e331. doi: 10.1038/cddis.2012.71. Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Mecha M1, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza C. Abstract Cannabidiol (CBD) is the most abundant cannabinoid in Cannabis sativa that has no psychoactive properties. CBD has been approved to treat inflammation, pain and spasticity associated with multiple sclerosis (MS), of which demyelination and oligodendrocyte loss are hallmarks. Thus, we investigated the protective effects of CBD against the damage to oligodendrocyte progenitor cells (OPCs) mediated by the immune system. Doses of 1 µM CBD protect OPCs...

Read more →

Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice.

Posted by Joe Pavlik on

Published: J Immunotoxicol. 2013 Jul-Sep;10(3):321-8. doi: 10.3109/1547691X.2012.741628. Epub 2012 Nov 23. Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. Karmaus PW, Wagner JG, Harkema JR, Kaminski NE, Kaplan BL. Abstract Cannabidiol (CBD) is a plant-derived cannabinoid that has been predominantly characterized as anti-inflammatory. However, it is clear that immune effects of cannabinoids can vary with cannabinoid concentration, or type or magnitude of immune stimulus. The present studies demonstrate that oral administration of CBD enhanced lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. The enhanced inflammatory cell infiltrate as observed in bronchoalveolar lavage fluid (BALF) was comprised mainly of neutrophils,...

Read more →

Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.

Posted by Joe Pavlik on

Published: Eur Neurol. 2014;72 Suppl 1:6-8. doi: 10.1159/000367615. Epub 2014 Sep 26. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways. Centonze D. Abstract BACKGROUND: Spasticity arises from hyperexcitability of the neural stretch reflex arc secondary to injury of the corticospinal tract. In response to injury, the density of glutamatergic inputs from afferent 1A fibers to motor neurons increases dramatically and adaptive changes occur in the morphology of microglia cells in the spinal cord. SUMMARY: Involvement of the endocannabinoid system in pathophysiological mechanisms responsible for spasticity has been demonstrated in animal models of MS. Stimulation of...

Read more →

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Posted by Joe Pavlik on

Published: Lancet. 2003 Nov 8;362(9395):1517-26. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group. Abstract BACKGROUND: Multiple sclerosis is associated with muscle stiffness, spasms, pain, and tremor. Much anecdotal evidence suggests that cannabinoids could help these symptoms. Our aim was to test the notion that cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclerosis. METHODS: We did a randomised, placebo-controlled trial, to which we enrolled 667 patients with...

Read more →

A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.

Posted by Joe Pavlik on

Published: Daru. 2015 Oct 21;23:48. doi: 10.1186/s40199-015-0131-8. A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis. Giacoppo S, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E. Abstract BACKGROUND: The present study was designed to investigate the efficacy of a new formulation of alone, purified cannabidiol (CBD) (>98 %), the main non-psychotropic cannabinoid of Cannabis sativa, as a topical treatment in an experimental model of autoimmune encephalomyelitis (EAE), the most commonly used model for multiple sclerosis (MS). Particularly, we evaluated whether administration of a topical 1 % CBD-cream, given at...

Read more →